ProImmune Launches Novel Class-Leading CFSE T Cell Proliferation Assays For Assessing Drug Immunogenicity Risk

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

Combined with ProImmune’s unique cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.

Unlike traditional assays, which are based on radioactive thymidine incorporation, ProImmune’s new assays utilise powerful flow cytometry methods, enabling accurate determination of the percentage of proliferating CD4-positive cells and detailed phenotyping of T cell responses with significantly improved overall sensitivity.

Dr. Nikolai Schwabe, CEO of ProImmune, said: “Our customers have come to expect ProImmune to deliver technology leadership without compromise. The launch of our CFSE T cell proliferation assays joins with our unequalled capability in class II HLA binding assays, delivering the most powerful in vitro assay platform on the market for assessing drug immunogenicity risk.”

Source
ProImmune

source : www.medicalnewstoday.com

Related News:

• Greater Infection Risk with Staples in Hip Surgery (CME/CE)
• SGO: No Lung CA Risk Seen with Estrogen (CME/CE)
• Genetic variations influence statin efficacy for lowering colon cancer risk
• Heart transplant patients face greater risk of skin cancer
• Risk Factor Analysis In A Contemporary Cystectomy Cohort Using Standardized Reporting Methodology And Adverse Event Criteria
• Greater Infection Risk with Staples in Hip Surgery
• SIR: ABI Flags Those Not Otherwise at Risk for CVD
• Broken Hip Increases 10-Year Death Risk
• The Body’s Anticipation Of A Meal Can Be A Diabetes Risk Factor
• No Increased Risk of Death with ‘The Pill’